BioLargo Inc (OTCQB:BLGO) said that its current projects are “major growth catalysts,” as it shared updates on its three key projects with investors.
"These initiatives are still unfolding, and in some cases, such as with PFAS testing on behalf of clients, we have to handle confidential information carefully," said Dennis P. Calvert, CEO of BioLargo in a statement. "Still, we believe it's important for our investors and followers to stay abreast of the progress of these projects that represent the key growth catalysts for our company."
READ: BioLargo says its Aqueous Electrostatic Concentrator eliminates multiple PFAS compounds in testing with client water
One of its projects passed the ‘factory acceptance testing’ this week after it was conducted by both BioLargo and Garratt-Callahan engineers at BioLargo's Oak Ridge, Tennessee facility.
The commercial prototype of the new "minimal liquid discharge" water treatment system was invented by North America's largest privately-held water treatment company, Garratt-Callahan, and engineered and built by BioLargo. The new water treatment system is designed to reuse and recycle, rather than discharge, treated wastewater, resulting in lower operational costs and less environmental impact for customers.
At this week's performance testing, the system removed over 98% of the target contaminants from water provided by a Garratt-Callahan client in continuous operation, in line with results achieved by Garratt-Callahan's original bench-scale and batch processing tests.
"This technology represents a dramatic, game-changing shift in how we manage industrial water for a more sustainable future," Kelle Zeiher, technical project manager at Garratt-Callahan, said.
PFAS treatment solution
For its second project, BioLargo said that the commercialization of its revolutionary PFA chemical removal system, the "Aqueous Electrostatic Concentrator", or AEC, is progressing.
While the company can't give details on confidential client communications, nor reveal details of new innovations, it has recently completed a series of further studies with a potential client's water to optimize technical and economic metrics and simulate the real-world conditions of a commercial trial. BioLargo's engineers are currently preparing a final techno-economic case study report for the client that will be integral for establishing in-field trials at the client's facilities, as well as at other prospective customers' sites.
BioLargo engineers recently completed in-house testing of the AEC using PFAS-contaminated water and internal preliminary testing shows the AEC eliminated a toxic soup of PFAS from the water stream. The chemicals, resistant to breaking down in the environment, are known as per and fluoroalkyl substances, or PFAS.
On the commercial side, BioLargo is in discussions with both prospective customers and potential channel partners to develop and support sales and distribution of the AEC.
Pet odor product
For BioLargo’s pet odor control product, the company said that its strategic partner, Ikigai Marketing Works LLC, are working together to support Ikigai's roll-out of a new pet odor control product based on BioLargo's proprietary technology.
The two companies have completed test marketing and their product orders from BioLargo thus far have exceeded the company's expectations. Ikigai is comprised of veteran consumer product executives with experience launching and growing multiple blockbuster consumer products.
"We are making steady progress towards commercialization of our water treatment systems and have the benefit of working with experienced channel partners to get there,” said Calvert. “We're also highly encouraged by the performance of the pet odor product being rolled out by partners at Ikigai.”
Contact Ritika at ritika@proactiveinvestors.com